135例胸腺瘤的诊断和外科治疗

来源 :现代医学 | 被引量 : 0次 | 上传用户:jjjjjj8610
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
目的:总结胸腺瘤的诊断和外科治疗经验。方法:回顾性分析2001年1月至2008年12月在我科手术治疗的135例胸腺瘤患者的临床资料。结果:肿瘤完整切除123例,部分切除12例,肿瘤完整切除率91%(123/135)。住院死亡1例。5年内复发8例,复发率6%(8/134);11例失随访。重症肌无力(MG)发生率为40%(54/135),术后MG症状完全缓解21例(溴吡啶斯的明停药),改善30例(溴吡啶斯的明剂量显著减少),改善不明显或加重3例(溴吡啶斯的明需维持原剂量、增加剂量或加用皮质激素等)。结论:胸部增强CT等影像学检查是诊断胸腺瘤的主要手段。重症肌无力是常见伴随症状;胸腺瘤不宜单纯切除,无论病理分期如何均应行扩大切除,以降低复发率;Ⅱ期及以上病变进行综合治疗可提高疗效。 Objective: To summarize the experience of diagnosis and surgical treatment of thymoma. Methods: The clinical data of 135 patients with thymoma treated surgically in our department from January 2001 to December 2008 were retrospectively analyzed. Results: There were 123 cases of complete tumor resection and 12 cases of partial resection. The rate of complete tumor resection was 91% (123/135). One patient died in hospitalization. 8 cases recurred within 5 years and the recurrence rate was 6% (8/134); 11 cases were missing follow-up. The incidence of myasthenia gravis (MG) was 40% (54/135). Postoperative MG symptoms were completely relieved in 21 patients (Brown Pyridoxine discontinuation), and 30 patients improved (bright Pyridoxine significantly reduced dose). Insignificant or aggravated in 3 cases (Brown Pyridoxine need to maintain the original dose, increase the dose or add corticosteroids, etc.). Conclusion: Thoracic enhanced CT and other imaging examinations are the main methods for the diagnosis of thymoma. Myasthenia gravis is a common concomitant symptom; thymoma should not be simply removed, regardless of the pathological stage should be extended resection to reduce the recurrence rate; comprehensive treatment of stage II and above lesions can improve the efficacy.
其他文献
在空心板预制过程中因原材料质量、施工工艺、混凝土自身应力、外界环境等原因,导致梁体表面产生裂缝、蜂窝、麻面等,虽不影响空心板的正常使用,但严重影响了其外观质量。
随着国家对公路基础设施建设投入的加大,我国公路得到了突飞猛进的发展,为确保公路建设的质量,在工程建设中逐步形成了的技术性很强的书面文件,那就是竣工资料。加强竣工资料
目的:探讨一种临床上实用的磁共振成像(MRI)检测手段来预测股骨头坏死(osteonecrosis of thefemoral head,ONFH)的塌陷。方法:选择37例ARCO分期为Ⅰ期和Ⅱ期的ONFH患者,在MRI的中部
紫杉醇作为一种具有广谱抗癌活性的新药已成为科学工作者的研究热点,并且做了大量的工作.本文综述了国内外开发与利用红豆杉物种资源获得紫杉醇的研究进展.